Author Archives: Chandra Ganegoda

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI’s platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, ...

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study ...

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate ...

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of ...

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 ...

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase ...

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, ...

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ...

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study ...

BriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...